| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
|
| | Blosozumab Basic information |
| Product Name: | Blosozumab | | Synonyms: | Blosozumab;Research Grade Blosozumab(DHJ48702);Blosozumab (anti-SOST);Research Grade Blosozumab | | CAS: | 1132758-87-2 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Blosozumab Structure]() |
| | Blosozumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Blosozumab Usage And Synthesis |
| Uses | Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis[1][2]. | | in vivo | Blosozumab (1-100 mg/kg, i.v.) shows effects of hyperostosis in rats[1].
| Animal Model: | Sprague-Dawley rats [2] | | Dosage: | 1, 10, and 100 mg/kg | | Administration: | Intravenous injection (i.v.), once every 3 days (5-week study) or once weekly (6-month study) | | Result: | Observed the bone anabolic effects.
Showed significant bleeding and morbidity at 100 mg/kg.
Decreases in the numbers of platelets.
Increased number of bone marrow megakaryocytes at 100 mg/kg.
|
| | References | [1] Robert R Recker, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res. 2015 Feb;30(2):216-24. DOI:10.1002/jbmr.2351
[2] Daniel G Rudmann, et al. Rat-specific decreases in platelet count caused by a humanized monoclonal antibody against sclerostin. Toxicol Sci. 2012 Feb;125(2):586-94. DOI:10.1093/toxsci/kfr318 |
| | Blosozumab Preparation Products And Raw materials |
|